The raised guidance for both revenue and non-GAAP EPS signals management confidence in continued momentum. Monitor Q4 2026 results for execution against the raised targets and any updates on the longer-term strategic plan.
Price Chart
Executive Summary
Merit Medical reported Q3 2026 revenue of $416.2M (up 8.4% YoY) and non-GAAP EPS of $1.12 (up 22% YoY), beating consensus estimates of $410.6M and $1.04. The company raised its full-year 2026 revenue guidance to $1.635-$1.642B and non-GAAP EPS guidance to $4.33-$4.37, reflecting stronger-than-expected first nine months.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $416.2M vs consensus $410.6M (beat)
- Non-GAAP EPS $1.12 vs consensus $1.04 (beat, +7.7%)
- Revenue growth 8.4% YoY; organic constant currency revenue growth 8.9%
- Non-GAAP operating margin expanded to 21.3% from 19.7% YoY
- Full-year 2026 revenue guidance raised to $1.635-$1.642B (prior $1.631-$1.643B)
- Full-year 2026 non-GAAP EPS guidance raised to $4.33-$4.37 (prior $4.25-$4.35)
- GAAP EPS $0.70 vs $0.46 YoY; GAAP operating margin 14.1% vs 11.1% YoY
- Cash flow from operations $175.2M YTD; free cash flow $129.5M YTD
Financial Impact
Revenue beat of ~$5.6M (1.4%) and EPS beat of $0.08 (7.7%) vs consensus; guidance raised for both revenue and EPS
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Foundational - Access | $157.9M | +4.0% |
| Foundational - OEM | $46.3M | +12.0% |
| Foundational - Procedural Solutions | $27.2M | -16.0% |
| Foundational - Vascular Intervention | $42.4M | +20.0% |
| Foundational - Other | $2.0M | +808.0% |
| Therapeutic - Cardiac Therapies | $27.5M | +8.0% |
| Therapeutic - Endoscopy | $23.4M | +33.0% |
| Therapeutic - OEM | $13.1M | +32.0% |
| Therapeutic - Oncology | $27.1M | +16.0% |
| Therapeutic - Renal Therapies | $13.6M | -2.0% |
| Therapeutic - Vascular Intervention | $35.8M | +8.0% |
Risk Factors
- Geopolitical instability (US-Israel-Iran conflict) could impact operations
- Integration risks from recent acquisitions (Solo Pace, View Point, C2, Biolife)
- Trade policy and tariff uncertainties
- Foreign exchange headwinds (constant currency revenue growth 8.1% vs reported 8.4%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391840 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Oct 29, 2026 3d ago | Press Release | $93.39 | awaiting T+60 | awaiting T+60 | $86.24 (−7.66%) |
Oct 29, 2026 3d ago | Press Release | $93.39 | awaiting T+60 | awaiting T+60 | $86.24 (−7.66%) |
Oct 27, 2026 4d ago | Institutional Cluster | $92.21 | awaiting T+60 | awaiting T+60 | $86.24 (−6.47%) |
Jul 2, 2026 17w ago | Press Release | $71.09 $87.00 | ▲ +22.38% | ▲ +18.81% | $86.24 (+21.31%) |
May 5, 2026 25w ago | Insider Cluster | $60.44 $83.35 | ▲ +37.91% | ▲ +35.17% | $86.24 (+42.69%) |
May 5, 2026 25w ago | Insider Cluster | $60.44 $83.35 | ▲ +37.91% | ▲ +35.17% | $86.24 (+42.69%) |
Apr 30, 2026 26w ago | Press Release | $62.01 $78.29 | ▲ +26.25% | ▲ +23.18% | $86.24 (+39.07%) |
Apr 16, 2026 28w ago | Court Ruling | $70.10 $73.26 | ▲ +4.51% | ▼ −2.54% | $86.24 (+23.02%) |
Apr 13, 2026 28w ago | 8-K | $70.54 $71.46 | ▲ +1.30% | ▼ −7.22% | $86.24 (+22.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers